Skip to content

Investor confidence bolstered by SetPoint Medical's funding for neuromodulation strategies targeting autoimmune disorders, as reported by GlobalData.

The SetPoint System works on the body's neural pathways to control immune system responses, providing a fresh, drug-free therapeutic approach that may significantly decrease the need for conventional medications like biologics and immune-suppressants.

Investor faith underscores Neuromodulation Methods for Autoimmune Disorders by SetPoint Medical:...
Investor faith underscores Neuromodulation Methods for Autoimmune Disorders by SetPoint Medical: GlobalData (rephrased)

Investor confidence bolstered by SetPoint Medical's funding for neuromodulation strategies targeting autoimmune disorders, as reported by GlobalData.

In the ever-evolving landscape of healthcare, two significant developments have emerged.

Firstly, the role of robotics in kidney-preserving cancer care is gaining attention. While the specifics of this application remain undisclosed, it promises to bring about a revolution in cancer treatment, preserving kidney function and potentially improving the quality of life for patients.

In a separate development, Sandeep Dogra has been appointed as the Group COO of ShardaCare Healthcity and Sharda Hospital. With over 25 years of experience in healthcare leadership, Dogra has served as Chief Revenue Officer at Sharda Hospital and held key roles at institutions like Max Healthcare and Fortis Healthcare. The context and purpose of his appointment are yet to be revealed.

Meanwhile, DPIIT (Department for Promotion of Industry and Internal Trade) has signed an MoU with Pfizer. This partnership aims to accelerate the lab-to-market journey of healthcare products, potentially paving the way for faster and more efficient healthcare solutions. The nature of the MoU and its potential impact on the healthcare industry are still under investigation.

On a related note, Dr. Jitendra Singh, Union Minister for Science and Technology, has called for scientifically authenticated information on obesity and metabolic disorders. This call comes as the current state of these conditions in the country remains unclear, along with any ongoing research or initiatives related to them.

Addressing the shortages, exodus, and education gaps in the field of medicine is another pressing concern. While no specific strategies or interventions have been revealed yet, Dr. Singh's call for information suggests a proactive approach towards addressing these issues.

Lastly, the WHO's addition of rapid-acting insulin analogues and GLP-1 receptor agonists to the Essential Medicines List (EML) is a significant step forward in diabetes management. However, the specifics of this addition and its implications for healthcare access and affordability are yet to be determined.

As these developments unfold, it is clear that the future of healthcare in India is marked by collaboration, innovation, and a commitment to improving patient care. Stay tuned for more updates as these stories continue to evolve.

Read also:

Latest